MA51203A - Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline - Google Patents
Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothélineInfo
- Publication number
- MA51203A MA51203A MA051203A MA51203A MA51203A MA 51203 A MA51203 A MA 51203A MA 051203 A MA051203 A MA 051203A MA 51203 A MA51203 A MA 51203A MA 51203 A MA51203 A MA 51203A
- Authority
- MA
- Morocco
- Prior art keywords
- sglt
- endothelin
- inhibitor
- treatment
- combination
- Prior art date
Links
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017081050 | 2017-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51203A true MA51203A (fr) | 2020-10-07 |
Family
ID=64606962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051203A MA51203A (fr) | 2017-11-30 | 2018-11-29 | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12144811B2 (enExample) |
| EP (1) | EP3716979B1 (enExample) |
| JP (2) | JP7404235B2 (enExample) |
| KR (1) | KR20200094187A (enExample) |
| CN (1) | CN111405899B (enExample) |
| AU (1) | AU2018376263B2 (enExample) |
| BR (1) | BR112020010831A2 (enExample) |
| CA (1) | CA3083327A1 (enExample) |
| CL (1) | CL2020001394A1 (enExample) |
| DK (1) | DK3716979T3 (enExample) |
| EA (1) | EA202091324A1 (enExample) |
| ES (1) | ES3035734T3 (enExample) |
| FI (1) | FI3716979T3 (enExample) |
| HR (1) | HRP20250732T1 (enExample) |
| HU (1) | HUE071739T2 (enExample) |
| IL (1) | IL274943B2 (enExample) |
| LT (1) | LT3716979T (enExample) |
| MA (1) | MA51203A (enExample) |
| MX (1) | MX2020005543A (enExample) |
| MY (1) | MY210547A (enExample) |
| PH (1) | PH12020550745A1 (enExample) |
| PL (1) | PL3716979T3 (enExample) |
| PT (1) | PT3716979T (enExample) |
| RS (1) | RS66980B1 (enExample) |
| SG (1) | SG11202004862XA (enExample) |
| SI (1) | SI3716979T1 (enExample) |
| TW (1) | TWI809009B (enExample) |
| UA (1) | UA127083C2 (enExample) |
| WO (1) | WO2019106066A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7223701B2 (ja) | 2017-02-27 | 2023-02-16 | イドーシア ファーマシューティカルズ リミテッド | ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤 |
| US11723929B2 (en) | 2017-06-13 | 2023-08-15 | The Regents Of The University Of California | Methods of improving cell-based therapy |
| CN114630668B (zh) * | 2019-11-07 | 2024-02-27 | 苏州科睿思制药有限公司 | 一种Aprocitentan晶型及其制备方法和用途 |
| CA3156136A1 (en) * | 2019-11-07 | 2021-05-14 | Michael Hadd | Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals |
| TW202133850A (zh) * | 2019-11-26 | 2021-09-16 | 瑞士商艾克泰聯製藥有限公司 | 用於治療經Ｆｏｎｔａｎ氏手術緩解之患者之肺血管疾病及／或心臟功能異常的醫藥組成物 |
| IL293921A (en) | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| CR20230083A (es) | 2020-07-10 | 2023-05-16 | Astrazeneca Ab | Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| KR20230149329A (ko) * | 2020-07-27 | 2023-10-26 | 아스트라제네카 아베 | 다파글리플로진을 이용하여 만성 신장 질환을 치료하는 방법 |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| AU2022340358A1 (en) * | 2021-09-02 | 2024-01-04 | Daewoong Therapeutics Inc. | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| AU2023276826A1 (en) | 2022-05-22 | 2025-01-09 | Idorsia Pharmaceuticals Ltd | Aprocitentan for the treatment of hypertension |
| EP4532472A1 (en) | 2022-05-25 | 2025-04-09 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| CN120265775A (zh) * | 2022-11-10 | 2025-07-04 | 瑞泽恩制药公司 | 用血管生成素样3(angptl3)抑制剂和溶质载体家族5成员2(slc5a2)抑制剂的组合治疗肾脏疾病 |
| CN120390636A (zh) * | 2022-12-20 | 2025-07-29 | 斯法姆公司 | 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的口服药物制剂 |
| WO2025089933A1 (ko) * | 2023-10-24 | 2025-05-01 | 주식회사 레드엔비아 | Sglt-2 저해제 및 dpp-4 저해제를 포함하는 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| KR100819668B1 (ko) | 2000-12-18 | 2008-04-04 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘-설퍼아마이드 |
| JP4035052B2 (ja) | 2000-12-28 | 2008-01-16 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体及びその医薬用途 |
| DE60237580D1 (de) | 2001-02-27 | 2010-10-21 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| KR100942622B1 (ko) | 2003-08-01 | 2010-02-17 | 미쓰비시 타나베 파마 코퍼레이션 | 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물 |
| UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
| NZ549219A (en) | 2004-03-04 | 2010-08-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| EP2360164A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CA2655144A1 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| AR061627A1 (es) | 2006-06-27 | 2008-09-10 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物 |
| CN102639125A (zh) * | 2009-05-27 | 2012-08-15 | 百时美施贵宝公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EA033286B1 (ru) * | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
| WO2015116880A1 (en) | 2014-01-31 | 2015-08-06 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| WO2015139386A1 (zh) | 2014-03-19 | 2015-09-24 | 杭州普晒医药科技有限公司 | 坎格列净一水合物及其晶型、它们的制备方法和用途 |
| KR20160132887A (ko) * | 2014-04-04 | 2016-11-21 | 사노피 | 당뇨, 비만, 이상지질혈증 및 관련 장애 치료를 위한 gpr119 조절자로서의 치환된 인다논 화합물 |
| CN106714796A (zh) | 2014-05-16 | 2017-05-24 | 阿斯利康(瑞典)有限公司 | 用于抑制sglt2抑制剂的胰高血糖素分泌的方法 |
| WO2016073846A1 (en) | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| WO2017064679A1 (en) | 2015-10-15 | 2017-04-20 | Lupin Limited | Process for the preparation of amorphous canagliflozin |
| JP7223701B2 (ja) | 2017-02-27 | 2023-02-16 | イドーシア ファーマシューティカルズ リミテッド | ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤 |
-
2018
- 2018-11-29 MA MA051203A patent/MA51203A/fr unknown
- 2018-11-29 SG SG11202004862XA patent/SG11202004862XA/en unknown
- 2018-11-29 JP JP2020529550A patent/JP7404235B2/ja active Active
- 2018-11-29 AU AU2018376263A patent/AU2018376263B2/en active Active
- 2018-11-29 EA EA202091324A patent/EA202091324A1/ru unknown
- 2018-11-29 UA UAA202003789A patent/UA127083C2/uk unknown
- 2018-11-29 EP EP18814821.7A patent/EP3716979B1/en active Active
- 2018-11-29 HR HRP20250732TT patent/HRP20250732T1/hr unknown
- 2018-11-29 BR BR112020010831-6A patent/BR112020010831A2/pt unknown
- 2018-11-29 FI FIEP18814821.7T patent/FI3716979T3/fi active
- 2018-11-29 IL IL274943A patent/IL274943B2/en unknown
- 2018-11-29 WO PCT/EP2018/082947 patent/WO2019106066A1/en not_active Ceased
- 2018-11-29 US US16/768,604 patent/US12144811B2/en active Active
- 2018-11-29 HU HUE18814821A patent/HUE071739T2/hu unknown
- 2018-11-29 PT PT188148217T patent/PT3716979T/pt unknown
- 2018-11-29 LT LTEPPCT/EP2018/082947T patent/LT3716979T/lt unknown
- 2018-11-29 PL PL18814821.7T patent/PL3716979T3/pl unknown
- 2018-11-29 KR KR1020207018658A patent/KR20200094187A/ko not_active Ceased
- 2018-11-29 MX MX2020005543A patent/MX2020005543A/es unknown
- 2018-11-29 CA CA3083327A patent/CA3083327A1/en active Pending
- 2018-11-29 CN CN201880076562.0A patent/CN111405899B/zh active Active
- 2018-11-29 ES ES18814821T patent/ES3035734T3/es active Active
- 2018-11-29 MY MYPI2020002671A patent/MY210547A/en unknown
- 2018-11-29 DK DK18814821.7T patent/DK3716979T3/da active
- 2018-11-29 TW TW107142595A patent/TWI809009B/zh active
- 2018-11-29 RS RS20250663A patent/RS66980B1/sr unknown
- 2018-11-29 SI SI201831245T patent/SI3716979T1/sl unknown
-
2020
- 2020-05-27 CL CL2020001394A patent/CL2020001394A1/es unknown
- 2020-05-29 PH PH12020550745A patent/PH12020550745A1/en unknown
-
2023
- 2023-12-13 JP JP2023209979A patent/JP7635355B2/ja active Active
-
2024
- 2024-10-28 US US18/929,609 patent/US20250120973A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51203A (fr) | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline | |
| MA49664A (fr) | Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline | |
| EP3370703A4 (en) | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES | |
| EP3612181A4 (en) | Combination therapies with ehmt2 inhibitors | |
| EP3908270A4 (en) | COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION | |
| EP3448875A4 (en) | Compositions for the treatment of disease | |
| MA45192A (fr) | Traitement d'association | |
| IL291030A (en) | Conjugated hepcidin mimetics | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| ME03314B (me) | Irnk terapija za liječenje očnih oboljenja | |
| EP3383404A4 (en) | CANCER TREATMENT USING 2-DEOXY-2-FLUORL-FUCOSE IN COMBINATION WITH A CHECKPOINT INHIBITOR | |
| EP3692028A4 (en) | INHIBITION OF UBIQUITIN-SPECIFIC PEPTIDASE 30 | |
| EP3324973A4 (en) | SYSTEMS AND METHOD FOR EYE TREATMENT WITH A PHOTOSENSIBILIZER | |
| MA47503A (fr) | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales | |
| EP2967062A4 (en) | DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION | |
| EP3370725A4 (en) | PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP4085053A4 (en) | TREATING CANCER WITH CDK12/13 INHIBITORS | |
| EP3846855A4 (en) | CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT | |
| EP3866777A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| EP3481393A4 (en) | COMBINATION OF A PD-L ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER | |
| EP3805216A4 (en) | COMPOUNDS TO TREAT OR PREVENT LIVER DISEASES | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| EP4017349A4 (en) | Therapeutic apparatus | |
| EP3877402A4 (en) | COMBINATION TREATMENT AGAINST RESISTANT HYPERTENSION |